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Oral Presentations S21593 days (range 15 - 674) post HSCT. Fourteen (40%) were deter-
mined to have invasive ADV disease (7 on tissue biopsy). ADV viral
load evaluation over time revealed the following: HVL at presenta-
tion in 18 (51.4%) (median 1.1x104,range 7.4x105 - 6.8x109 copies/
ml); 10 (28%) progressed to HVL (median 2 log increase from pre-
sentation) at a median of 15 days (range 3 - 56); and LVL-only at any
time point in 7 (20%) pts (median 4000 copies/ml, range 600 - 8866).
Fifteen pts with HVL were treated with cidovofir intravenously or/
and CMX001 a median 7 doses (range 1 - 38). Despite treatment
with antiviral therapy 12 pts (92%) with HVL and 7 pts (87.5%)
with LVL-HVL died. Mortality was attributable to ADV in 11
(31.4%) pts. All cause 180 day mortality was 74.3% for pts with
ADV.
Conclusions: ADV viremia was relatively low (8.7%) in this high
risk population and similar to the 5% reported in populations receiv-
ing conventional transplants. Determination of viral status in pa-
tients with clinical symptoms resulted in a relatively high yield of
positivity - 40%. Themortality attributable to ADVof 30% suggests
the need for development of better treatment modalities. The 180
day all cause mortality of 74% suggests ADV viremia complicates
other medical conditions and complications of transplant.
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COINFUSION OF HAPLO-IDENTICAL DONOR STEM CELLS WITH AN (UN)
RELATED CORD TRANSPLANT PROVED TO BE SUCCESSFUL IN A VERY
HIGH RISK GROUP OF PATIENTS
Lindemans, C.A.1, Kuball, J.H.2, L.C. te Boome2, Versluys, A.B.1,
Bierings, M.B.1, Boelens, J.J.1 1University Medical Center Utrecht;
2University Medical Center Utrecht
Introduction: Combining haplo-donor stem cells with a full graft
cord blood (CB)-unit has been proposed as a cell support mechanism
which can make single CB available as a donor source for allogeneic
HSCT to a larger proportion of patients: e.g. patients with only do-
nors available with low NC-counts, or with active infections.
Methods: Since 2009 we have a CB+haplo protocol for this group of
patients. Patients (with any indication) with active infection (e.g. fun-
gal) as well as patients with only a CB-unit available below the lower
acceptable cut off were offered a CB+Haplo grafting. All patients re-
ceived myeloablative conditioning (busulfan with therapeutic drug
monitoring in combination with either CY or FLU) and serotherapy
(ATG 8, Campath 1). Haplo-grafts were CD34+ selected (except 1:
CD3/CD19 negative selected). After infusion of the CB, the haplo-
graft containing 5milj/kg CD34+ cells were infused. G-CSF was
given from day +7. GvHD prophylaxis: CsA+pred 1mg/kg.
Results.: 9 patients (8 children, 1 adult; 8 with active infection, 1 low
cell count CBU). Median age was 12.4 yr (range 0.25-41.2 yr). 7 had
a non-malignant disease (5 immunodeficiencies, 1 Osteopetrosis, 1
AA), 2 had a malignant indication. For 2 patients it was their second
transplant. All patients except 1 engrafted at a median time of 12 days
(range 9-15). Thrombocyte engraftment (TBC50) was 36 days
(range14-300). EFS was 33% after a median follow up 249 days
(14-1245). Incidence of GvHD gr. 2-4 was 25%. The non-relapse
mortality was 2/9 (day 14 and day 24 respectively).The initial donor
chimerism at 1 month post SCT showed.80% haplo chimerism in
most patients but all 7 reached a full donor cord blood chimerism
(.95%) within a median period of 121 days (28-925 days) post SCT.
Conclusion: Coinfusion of Haplo with (unrelated) CB transplanta-
tion is a safe and effective option for a group of very high risk patients
(including patients with higher non-engraftment risks) to secure
early engraftment. Haplo-support leads to early haplo-engraftment
switching to full CB donor-chimerism within 4 months, allowing
a normal immune recovery and repertoire.34
CD8-DEPLETED DONOR-LYMPHOCYTE INFUSIONS AFTER T-CELL DE-
PLETED ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION
Wagner, E.M., Wehler, D., Kolbe, K., Theobald, M., Herr, W.,
Meyer, R.G. University Medical Center of the Johannes Gutenberg-Uni-
versity, Mainz, Germany
In a phase I/II clinical trial, we investigated the prophylactic use of
CD8-depleted (CD8depl) donor lymphocyte infusions (DLI) in thesetting of T-cell depleted allogeneic hematopoietic stem cell trans-
plantation (HSCT). T-cell depletion was carried out by the use of
high-dose Alemtuzumab (100 mg or 60 mg for unrelated or sibling
donor transplantation, respectively). Here, we provide clinical fol-
low-up data of 101 patients with different hematologic diseases
and a median observation time of 1.5 years (range, 6-84 months).
Median age was 56 years (range, 20-71). Stem cell source were pe-
ripheral blood stem cells of matched siblings (n 5 15), matched un-
related (n 5 48), or unrelated donors with single HLA mismatches
(n5 38). Tapering of Cyclosporin A was started in the 6th week after
transplantation. Subsequently, CD8depl DLI were administered pro-
phylactically in escalating doses starting with 1x106 CD4 T cells/kg
bodyweight. 39 patients received at least one dose of DLI. Among
patients who did not qualify for DLI, 46 patients had primary
GVHD. In 16 patients DLI were not administered for other reasons.
Following DLI, acute GVHDwas the major reason for withholding
subsequent DLI-doses (64%) and 30% suffered from acute GVHD
\ 2. Extensive chronic GVHD was diagnosed in 10% of the pa-
tients. The 1 and 3 year overall survival was 63% and 43%, respec-
tively. Survival significantly differed between the DLI and non
DLI group after 3 years (62% vs. 27%, p 5 0.002). When the DLI
group was compard to those patients who did not receive DLI for
other reasons than primary GVHD, the difference in overall survival
was similar (62% vs. 28%, p5 0.01). The presence of GVHD at any
time was associated with a reduced relapse rate (56% vs. 31%, p 5
0.013), independent of DLI.We demonstrated that 21 of 24 patients
(84%)with decreasingT-cell chimerism (TCC) converted to full do-
nor following CD8depl DLI. In contrast, only 2 of 8 patients (25%)
with decreasing TCC in the non-DLI group converted spontane-
ously.
In summary, we observed that the application of prophylactic
CD8depl DLI was associated with a survival benefit – even though
the nature of the trial does not argue for a causal relationship. Our
data strongly ask for randomized trials either comparing prophylac-
tic application of CD8depl DLI vs. no DLI or CD8depl vs. non-ma-
nipulated DLI in a preemptive setting.35
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POSSIBLE CURE OF HIV INFECTION
Petz, L.1, Tonai, R.1, Redei, I.2, Li, S.3, Li, H.3, Bryson, Y.4, Regan, D.5,
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Background: The most important mechanism for natural protec-
tion against HIV transmission is a mutation in the CCR5 gene lead-
ing to a 32-base-pair deletion (CCR5-delta32) and a non-functional
CCR5 protein. Prior to 2001, Chow et al pioneered the concept to
screen allogeneic stem cell donors for those homozygous for
CCR5-delta32 to transplant HIV infected patients (U.S. patent
2003/0099621 A1), as acknowledged by Hutter et al recently (The-
ScientificWorld Journal, 2011;11:1068-1076). Hutter et al (NEJM
2009;360:692-698) performed a bone marrow transplant in a patient
with acute leukemia who was infected with HIV using a donor ho-
mozygous for the CCR5-delta32 deletion. More than 4 years later
the patient does not require antiretrovial therapy and no viral load
or proviral DNA can be detected. However, this procedure cannot
be generalized using adult donors because the variant allele is quite
unusual (\1% of Caucasians, and much lower in other ethnic
groups) and a very close HLA match is required between adult do-
nors and patients.
Hypothesis: Cord blood HCT requires HLA matching of only 4 of
6 alleles. Therefore, our hypothesis is that an inventory of cord blood
S216 Oral Presentationsunits homozygous for the CCR5-delta32 allele will provide an im-
proved probability of finding an appropriately HLA-matched donor
for a patient with HIV infection in need of a HCT.
Methods: CCR5 genotype analysis is performed on DNA extracted
from cord blood using a PCR based assay. Biomathematicians at the
NMDP developed estimates regarding the probability of providing
an adequately HLA matched cord blood unit.
Results: We have tested about 10,000 cryopreserved cord blood
units and have identified 81 homozygous CCR5-delta32 units.
Testing an additional 25,000 cord blood units from Caucasians
is expected to increase the special inventory to about 300 units
which is projected to provide for Caucasians an adequately
HLA matched cord blood unit with an adequate cell dose for
73.61% of pediatric patients and 27.92% of adults. The initial
population for transplantation is patients in need of a HCT for
a hematologic malignancy or other indication, and who are also
infected with HIV, although some selected patients with AIDS
who have no other illness may also ultimately be considered for
transplantation.
Conclusions: Cord blood transplantation has a unique role in pro-
viding for long term control or possible cure of HIV infection.
Disclosure: No relevant conflicts of interest to declare.36
LONG TERM OUTCOMES FOR ALEMTUZUMAB BASED REDUCED INTEN-
SITY CONDITIONING TRANSPLANT FOR MYELODYSPLASTIC SYN-
DROMES AND ACUTE MYELOID LEUKAEMIA
Potter, V.T., Krishnamurthy, P., Tindell, V.J., Lim, Z., Ireland, R.,
Marsh, J.C., Pagliuca, A., Ghulam,M.J. Kings College Hospital, London,
United Kingdom; United Kingdom; United Kingdom
Haematopoietic Stem Cell Transplantation (HSCT) remains
the only curative therapy for patients with myelodysplastic syn-
dromes (MDS) and acute myeloid leukaemia with tri-lineage dys-
plasia (TLD-AML). Reduced intensity conditioning (RIC) has
expanded this approach to older patients and to those with co-
morbidities. Previously published data from our institution has
shown excellent overall survival and low rates of GVHD at one
year with alemtuzumab-based RIC-HSCT. Herein we report
the long-term follow-up data of 237 patients with high risk
MDS and TLD-AML treated at our institution from 1999 to
June 2010.
All patients received a conditioning protocol consisting of fludar-
abine (150mg/m2), busulphan and alemtuzumab (100mg) from sib-
ling (n 5 57) or matched unrelated donors (MUD) (n 5 180). 30
patients received 4 days of busulphan (total dose 12.8mg/kg iv or
16mg po) while the remainder received 2 days (total dose 6.4mg/
kg iv 8mg po). The majority of patients receiving an unrelated
transplant had a fully matched donor (n 5 128), with 45 having
a 1-antigen mm donor and 7 having a 2-antigen mm donor. The
median age of the cohort was 56 years (range:19-72) and median
follow-up for survivors was 5.2 years (range:0.12-11.4). OS and
DFS for the entire cohort was 44% and 34% respectively at five years
with no significant difference between sibling andMUD transplants.
NRM was 23% at one year and 31% at five years. Relapse at five
years was 51%. Acute GVHD occurred in 35% and chronic
GVHD in 27%. The rate of extensive de-novo chronic GVHD
was very low at 10%. Outcomes were similar for those receiving
four doses of busulphan despite a higher proportion of patients not
in CR at the time of HSCT in this group.
On multivariate analysis, age remained the only significant fac-
tor with regard to OS, DFS and NRM. For patients aged less than
60 vs greater than 60 years at five years OS was 55 vs 23%, DFS
was 46 vs 15% and NRM 27 vs 50%. To our knowledge this
analysis represents the largest series of patients receiving alemtu-
zumab based RIC for MDS and TLD-AML. Long-term out-
comes remain excellent for younger patients. Novel strategies
are required for the prevention of relapse and to improve out-
comes in older patients.37
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The Myeloproliferative Disorder-Research Consortium (MPD-
RC) designed the first US prospective phase II study of reduced in-
tensity allogeneic hematopoietic stem cell transplantation (HSCT)
in patients with primarymyelofibrosis (PMF) orMF secondary to es-
sential thrombocythemia (ET-MF) or polycythemia vera (PV-MF).
Between May 2007 and March 2011, 66 patients were enrolled into
MPD-RC 101 study and transplanted from related (n5 32) or unre-
lated (n 5 34) donors using a fludarabine/melphalan 6 ATG regi-
men. Of 66 patients, 63 were at intermediate/high risk according
to Lille score system and 3 low risk patients had thrombocytopenia.
Recipients of related and unrelatedHSCTwere comparable with re-
spect to age (median: 54 vs 55 years), gender, Lille score, time from
diagnosis to transplant, presence of Jak-2 V617F mutation, spleno-
megaly and splenectomy. Donors were HLA matched in 94% of re-
lated and 74% of unrelated transplants. Engraftment of neutrophils
and platelets occurred in 31/32 related and 26/34 unrelated trans-
plants. Five secondary graft failures occurred (4 among unrelated re-
cipients). Median time to ANC . 0.5 x 109/L and platelets .20 x
109/L engraftment was: day 22 and 28 in the related, and day 18
and 28 in the unrelated cohort, respectively. Acute GVHD grade
II-IV occurred in 37% related (grade III-IV: 12%) and 42% unre-
lated transplants (grade III-IV: 21%). In patients with $ 6 months
follow-up, there were 7 CR, 8 PR, and 11 CI according to the
IWG criteria among the 28 patients in the related group, and 5
CR, 1 PR, and 5 CI among the 16 patients in the unrelated group.
After a median follow-up of 24 months for survivors in the related
group, 78% of the patients are alive, TRM was 18% and relapse-re-
lated mortality was 3%. In the unrelated group, 44% of the patients
are alive after 12months follow-up, TRMwas 53% and 3% died due
to relapse. Median survival time has not been reached in the related
group and is 7 months in the unrelated group (hazard ratio 4.2, 95%
CI: 1.7-10.1, p\0.001). Survival in unrelated transplants was not as-
sociated with PBSC or BMHSCT, HLAmatching, diagnosis, Jak-2
mutation. In this prospective study a reduced intensity allogeneic
HSCTwith Flu/Mel regimen was very effective in myelofibrosis pa-
tients transplanted from related donors. In unrelated transplants,
a high rate of primary or secondary graft failure led to a high rate
of TRM. For these patients a different conditioning regimen may
be required.38
IDENTIFICATION AND CHARACTERIZATION OF H-Y SPECIFIC ALLOGE-
NEIC B CELLS FOLLOWING SEX-MISMATCHED TRANSPLANTATION
Sahaf, B., Perloff, S.H., Wu, F., Miklos, D.B. Division of Blood andMar-
row Transplantation, Stanford University School of Medicine
H-Y allo-antibody develop in association with chronic graft-ver-
sus-host disease (cGVHD) following sex-mismatched transplant.
We hypothesize that H-Y specific B cells contribute to cGVHD
pathogenesis and have developed H-Y specific FACS stain for their
isolation and characterization.
